On October 17, Governor Newsom announced that California will be launching the “first and only” state contracted affordable insulin. Through an agreement with nonprofit generic drug manufacturer Civica Rx and Biocon Biologics, the interchangeable biosimilar insulin glargine pen CALRX will be available for purchase from January 1, 2026. The announcement noted that the launch of
Latest Post
More Posts
FDA Updates Guidance on Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment & other Quality-Related Considerations
Samsung Bioepis Secures Marketing Approval in Korea for its Biosimilar to Amgen’s Bone Cancer Drug Xgeva
CuraTeQ Biologics’ Trastuzumab biosimilar Receives Positive Opinion in Europe
Celltrion Wins Costco Formulary Listing for its Recently Launched Ustekinumab
The 43rd Annual J.P. Morgan Healthcare Conference Starts Today – A Who’s Who in Biologics at this Year’s Conference
Alvotech Requests that FDA Refuse to License CHO-Cell Derived Ustekinumab Biosimilars as Interchangeable Until the Effects of Sialylation Are Evaluated
FTC Comment on FDA Draft Guidance on Interchangeability
Acuitas File Complaint Against Alnylam for Declaratory Judgment of Co-Inventorship of Lipid Particle Patents
FDA Approves Boehringer Ingelheim’s CYLTEZO® Biosimilar to Humira for Multiple Chronic Inflammatory Diseases
Subscribe: Subscribe via RSS
Blogs
Firm/Org